Lipocine (LPCN) Stock Forecast, Price Target & Predictions
LPCN Stock Forecast
Lipocine stock forecast is as follows: an average price target of $10.00 (represents a 113.68% upside from LPCN’s last price of $4.68) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
LPCN Price Target
The average price target for Lipocine (LPCN) is $10.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $10.00. This represents a potential 113.68% upside from LPCN's last price of $4.68.
LPCN Analyst Ratings
According to 1 Wall Street analysts, Lipocine's rating consensus is 'Buy'. The analyst rating breakdown for LPCN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Lipocine Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 24, 2024 | Scott Henry | Industrial Alliance Securities | $10.00 | $4.54 | 120.26% | 113.68% |
The latest Lipocine stock forecast, released on Sep 24, 2024 by Scott Henry from Industrial Alliance Securities, set a price target of $10.00, which represents a 120.26% increase from the stock price at the time of the forecast ($4.54), and a 113.68% increase from LPCN last price ($4.68).
Lipocine Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $10.00 | $10.00 |
| Last Closing Price | $4.68 | $4.68 | $4.68 |
| Upside/Downside | -100.00% | 113.68% | 113.68% |
In the current month, the average price target of Lipocine stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Lipocine's last price of $4.68. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 24, 2024 | Alliance Global Partners | Buy | Initialise |
Lipocine's last stock rating was published by Alliance Global Partners on Sep 24, 2024. The company Initialise its LPCN rating from "null" to "Buy".
Lipocine Financial Forecast
Lipocine Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $-3.12M | - | $54.99K | $9.50M | - | $500.00K | - | $-38.85K | - | - | $428.03K | - | - |
| Avg Forecast | $2.87M | $999.00K | $624.00K | $500.00K | $1.35M | $129.50K | $290.00K | $307.00K | $256.00K | $777.00K | $1.31M | $698.67K | $257.00K | $4.00M | $5.50M | $21.00 | $2.35K | $694.62K | $3.12K | $30.14K |
| High Forecast | $4.84M | $1.68M | $1.05M | $842.30K | $2.61M | $218.16K | $488.54K | $517.17K | $431.26K | $1.31M | $2.20M | $698.67K | $257.00K | $4.00M | $5.50M | $25.00 | $2.82K | $833.54K | $3.75K | $36.17K |
| Low Forecast | $905.80K | $315.07K | $196.80K | $157.69K | $83.00K | $40.84K | $91.46K | $96.82K | $80.74K | $245.06K | $411.90K | $698.67K | $257.00K | $4.00M | $5.50M | $16.00 | $1.88K | $555.69K | $2.50K | $24.11K |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 3 | 5 | 8 | 15 | 12 | 8 | 11 |
| Surprise % | - | - | - | - | - | - | - | -10.17% | - | 0.07% | 7.27% | - | 1.95% | - | -0.01% | - | - | 0.62% | - | - |
Lipocine's average Quarter revenue forecast for Jun 24 based on 1 analysts is $290.00K, with a low forecast of $91.46K, and a high forecast of $488.54K. LPCN's average Quarter revenue forecast represents a -109.29% decrease compared to the company's last Quarter revenue of $-3.12M (Sep 23).
Lipocine EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 3 | 5 | 8 | 15 | 12 | 8 | 11 |
| EBITDA | - | - | - | - | - | - | - | $-6.73M | $-3.57M | $-3.96M | $-2.26M | $-2.73M | $-3.46M | $-3.09M | $13.09M | $-5.64M | $-3.00M | $-2.52M | $-4.85M | $-7.00M |
| Avg Forecast | $-15.32K | $-5.33K | $-3.33K | $-2.67K | $-7.19K | $-690.00 | $-1.55K | $-1.64K | $-1.36K | $-4.14K | $-6.97K | $27.23K | $10.02K | $-3.40M | $214.39K | $-9.19M | $-3.12M | $-3.48M | $-5.56M | $-5.74M |
| High Forecast | $-4.83K | $-1.68K | $-1.05K | $-841.00 | $-442.00 | $-217.00 | $-487.00 | $-516.00 | $-430.00 | $-1.31K | $-2.20K | $27.23K | $10.02K | $-2.72M | $214.39K | $-7.35M | $-2.50M | $-2.79M | $-4.44M | $-4.59M |
| Low Forecast | $-25.81K | $-8.98K | $-5.61K | $-4.49K | $-13.94K | $-1.16K | $-2.61K | $-2.76K | $-2.30K | $-6.98K | $-11.74K | $27.23K | $10.02K | $-4.08M | $214.39K | $-11.03M | $-3.75M | $-4.18M | $-6.67M | $-6.89M |
| Surprise % | - | - | - | - | - | - | - | 4108.61% | 2613.91% | 956.17% | 324.54% | -100.35% | -344.92% | 0.91% | 61.04% | 0.61% | 0.96% | 0.72% | 0.87% | 1.22% |
3 analysts predict LPCN's average Quarter EBITDA for Mar 22 to be $-3.40M, with a high of $-2.72M and a low of $-4.08M. This is -125.96% lower than Lipocine's previous annual EBITDA (Dec 21) of $13.09M.
Lipocine Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 3 | 5 | 8 | 15 | 12 | 8 | 11 |
| Net Income | - | - | - | - | - | - | - | $-6.65M | $-3.55M | $-3.87M | $-2.23M | $-2.25M | $-1.74M | $-3.49M | $13.26M | $-5.77M | $-3.22M | $-2.72M | $-4.86M | $-7.01M |
| Avg Forecast | $-695.23K | $-1.50M | $-1.66M | $-1.71M | $-1.98M | $-2.59M | $-4.17M | $-3.21M | $-3.42M | $-2.27M | $-2.73M | $-3.03M | $-3.63M | $-3.84M | $-908.47K | $-11.54M | $-3.22M | $-3.76M | $-5.51M | $-5.70M |
| High Forecast | $-76.48K | $-164.73K | $-182.38K | $-188.26K | $-1.82M | $-285.33K | $-458.89K | $-352.99K | $-376.52K | $-250.03K | $-300.04K | $-3.03M | $-3.63M | $-3.07M | $-908.47K | $-9.23M | $-2.58M | $-3.00M | $-4.41M | $-4.56M |
| Low Forecast | $-1.31M | $-2.83M | $-3.13M | $-3.23M | $-2.14M | $-4.90M | $-7.88M | $-6.06M | $-6.47M | $-4.30M | $-5.15M | $-3.03M | $-3.63M | $-4.60M | $-908.47K | $-13.85M | $-3.87M | $-4.51M | $-6.61M | $-6.83M |
| Surprise % | - | - | - | - | - | - | - | 2.07% | 1.04% | 1.70% | 0.82% | 0.74% | 0.48% | 0.91% | -14.59% | 0.50% | 1.00% | 0.72% | 0.88% | 1.23% |
Lipocine's average Quarter net income forecast for Mar 22 is $-3.84M, with a range of $-4.60M to $-3.07M. LPCN's average Quarter net income forecast represents a -128.94% decrease compared to the company's last Quarter net income of $13.26M (Dec 21).
Lipocine SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 3 | 5 | 8 | 15 | 12 | 8 | 11 |
| SG&A | - | - | - | - | - | - | - | $1.04M | $1.44M | $1.29M | $890.34K | $798.94K | $1.13M | $1.24M | $-4.28M | $2.09M | $-773.39K | $309.96K | $-1.26M | $1.72M |
| Avg Forecast | $23.93M | $8.32M | $5.20M | $4.17M | $11.24M | $1.08M | $2.42M | $2.56M | $2.13M | $6.47M | $10.88M | $5.82M | $2.14M | $1.37M | $45.82M | $174.00 | $-773.39K | $428.04K | $-1.43M | $251.14K |
| High Forecast | $40.31M | $14.02M | $8.76M | $7.02M | $21.78M | $1.82M | $4.07M | $4.31M | $3.59M | $10.91M | $18.33M | $5.82M | $2.14M | $1.64M | $45.82M | $208.00 | $-618.72K | $513.65K | $-1.14M | $301.36K |
| Low Forecast | $7.55M | $2.63M | $1.64M | $1.31M | $691.52K | $340.29K | $762.04K | $806.71K | $672.70K | $2.04M | $3.43M | $5.82M | $2.14M | $1.09M | $45.82M | $133.00 | $-928.07K | $342.44K | $-1.71M | $200.90K |
| Surprise % | - | - | - | - | - | - | - | 0.41% | 0.68% | 0.20% | 0.08% | 0.14% | 0.53% | 0.91% | -0.09% | 11984.26% | 1.00% | 0.72% | 0.88% | 6.86% |
Lipocine's average Quarter SG&A projection for Jun 24 is $2.42M, based on 1 Wall Street analysts, with a range of $762.04K to $4.07M. The forecast indicates a 131.75% rise compared to LPCN last annual SG&A of $1.04M (Sep 23).
Lipocine EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 4 | 3 | 5 | 8 | 15 | 12 | 8 | 11 |
| EPS | - | - | - | - | - | - | - | $-1.26 | $-0.68 | $-0.74 | $-0.03 | $-0.03 | $-0.02 | $-0.04 | $0.15 | $-0.14 | $-0.14 | $-0.13 | $-0.26 | $-0.38 |
| Avg Forecast | $-0.13 | $-0.28 | $-0.31 | $-0.32 | $-0.37 | $-0.48 | $-0.78 | $-0.60 | $-0.64 | $-0.42 | $-0.51 | $-0.57 | $-0.68 | $-0.34 | $-0.17 | $-1.36 | $-2.46 | $-0.29 | $-0.34 | $-0.26 |
| High Forecast | $-0.01 | $-0.03 | $-0.03 | $-0.04 | $-0.34 | $-0.05 | $-0.09 | $-0.07 | $-0.07 | $-0.05 | $-0.06 | $-0.57 | $-0.68 | $-0.34 | $-0.17 | $-1.36 | $-2.46 | $-0.23 | $-0.27 | $-0.21 |
| Low Forecast | $-0.25 | $-0.53 | $-0.59 | $-0.60 | $-0.40 | $-0.92 | $-1.47 | $-1.13 | $-1.21 | $-0.80 | $-0.96 | $-0.57 | $-0.68 | $-0.34 | $-0.17 | $-1.36 | $-2.46 | $-0.35 | $-0.41 | $-0.31 |
| Surprise % | - | - | - | - | - | - | - | 2.10% | 1.06% | 1.74% | 0.05% | 0.04% | 0.03% | 0.12% | -0.88% | 0.10% | 0.06% | 0.45% | 0.76% | 1.46% |
According to 3 Wall Street analysts, Lipocine's projected average Quarter EPS for Mar 22 is $-0.34, with a low estimate of $-0.34 and a high estimate of $-0.34. This represents a -326.67% decrease compared to LPCN previous annual EPS of $0.15 (Dec 21).
Lipocine Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.52 | $70.00 | 13361.54% | Buy |
| RVPH | Reviva Pharmaceuticals | $1.40 | $10.00 | 614.29% | Buy |
| CKPT | Checkpoint Therapeutics | $3.72 | $20.00 | 437.63% | Buy |
| ZURA | Zura Bio | $2.51 | $10.00 | 298.41% | Buy |
| ARDX | Ardelyx | $4.66 | $11.00 | 136.05% | Buy |
| LPCN | Lipocine | $5.21 | $10.00 | 91.94% | Buy |
| VSTM | Verastem | $4.60 | $7.00 | 52.17% | Buy |
| KOD | Kodiak Sciences | $8.87 | $11.00 | 24.01% | Buy |